Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06463587
Registration number
NCT06463587
Ethics application status
Date submitted
11/06/2024
Date registered
18/06/2024
Date last updated
21/10/2026
Titles & IDs
Public title
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Query!
Scientific title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to Assess the Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Query!
Additional trial identifiers [1]
0
0
2023-507746-83-00
Query!
Additional trial identifiers [2]
0
0
MS700568_0183
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
Generalized Myasthenia Gravis
0
0
Query!
Condition category
Condition code
Inflammatory and Immune System
0
0
0
0
Query!
Autoimmune diseases
Query!
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
Other interventions - Placebo
Treatment: Drugs - Cladribine Low Dose
Treatment: Drugs - Cladribine High Dose
Placebo comparator: Placebo - DBPC Period: Participants will be administered with Placebo, orally as 2 separate treatment courses starting on Day 1 and at the beginning of Week 5.
BE Period: Participants initially randomized to placebo matched to cladribine in DBPC period will receive cladribine Low Dose or High Dose, orally as 2 separate treatment courses starting at the beginning of Week 25 and at the beginning of Week 29 and retreated if clinically justified with placebo matched to cladribine.
RT Period: If clinically justified, participants requiring retreatment with cladribine Low Dose or High Dose or cladribine supplemental dose will receive the selected dose of cladribine or matching placebo regimen.
Experimental: Cladribine Low Dose - DBPC Period: Participants will be administered with cladribine Low Dose, orally as 2 separate treatment courses starting on Day 1 and at the beginning of Week 5.
BE Period: Participants initially randomized to cladribine Low Dose in DBPC period will receive placebo matched to cladribine as 2 separate treatment courses starting at the beginning of Week 25 and at the beginning of Week 29 and retreated with cladribine supplemental dose if clinically justified.
RT Period: If clinically justified, participants requiring retreatment with cladribine Low Dose regimen and/or supplemental dose will receive the selected dose of cladribine or matching placebo regimen.
Experimental: Cladribine High Dose - DBPC Period: Participants will be administered cladribine High Dose, orally as 2 separate treatment courses starting on Day 1 and at the beginning of Week 5.
BE Period: Participants initially randomized to cladribine High Dose in DBPC period will receive placebo matched to cladribine as 2 separate treatment courses starting at the beginning of Week 25 and at the beginning of Week 29 and retreated with cladribine supplemental dose if clinically justified.
RT Period: If clinically justified, participants requiring retreatment with cladribine High Dose regimen and/or supplemental dose will receive the selected dose of cladribine or matching placebo regimen.
Other interventions: Placebo
Participants will receive placebo matched to cladribine in two courses separated by 4 weeks.
Treatment: Drugs: Cladribine Low Dose
Participants will receive cladribine low dose in two courses separated by 4 weeks.
Treatment: Drugs: Cladribine High Dose
Participants will receive cladribine high dose in two courses separated by 4 weeks.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Description of the comparator or control
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change from Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Scale Score at Week 24 During the Double-Blind Placebo Controlled (DBPC) Period
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Baseline, Week 24
Query!
Secondary outcome [1]
0
0
Change from Baseline in Quantitative Myasthenia Gravis (QMG) Scale Score at Week 24 During the Double-Blind Placebo Controlled (DBPC) Period
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Baseline, Week 24
Query!
Secondary outcome [2]
0
0
Percentage of MG-ADL Responders at Week 24 During the Double-Blind Placebo Controlled (DBPC) Period
Query!
Assessment method [2]
0
0
MG-ADL responder is defined by achieving \>= 3 points decrease in MG-ADL score.
Query!
Timepoint [2]
0
0
At Week 24
Query!
Secondary outcome [3]
0
0
Change from Baseline in Myasthenia Gravis Composite (MGC) Scale Score at Week 24 During the Double-Blind Placebo Controlled (DBPC) Period
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Baseline, Week 24
Query!
Secondary outcome [4]
0
0
Percentage of Quantitative Myasthenia Gravis (QMG) Scale Responders at Week 24 During the Double-Blind Placebo Controlled (DBPC) Period
Query!
Assessment method [4]
0
0
QMG responder is defined by achieving \>= 4 points decrease in QMG score.
Query!
Timepoint [4]
0
0
At Week 24
Query!
Secondary outcome [5]
0
0
Time From Initial Cladribine Full Dose Treatment to First Retreatment or Rescue Treatment up to end of Study
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Up to End of Study (Week 144)
Query!
Secondary outcome [6]
0
0
Number of Participants With Adverse Events (AEs) and Adverse Events of Special Interest (AESIs)
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Up to End of Study (Week 144)
Query!
Secondary outcome [7]
0
0
Number of participants with Adverse Events (AEs) by Severity as per National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Up to End of Study (Week 144)
Query!
Secondary outcome [8]
0
0
Number of Participants with Abnormal Laboratory Variables including Absolute Lymphocyte Count and Vital Signs
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Up to End of Study (Week 144)
Query!
Secondary outcome [9]
0
0
Pharmacokinetic (PK) Plasma Concentration of Cladribine
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Pre-dose, 0.25, 1, 2, 3, 4, 6, 8 and 24 hours post-dose
Query!
Secondary outcome [10]
0
0
Change from Baseline in the Revised Myasthenia Gravis Quality of Life - 15 Scale (MG-Qol15r) Score at Week 24 During the Double-Blind Placebo Controlled (DBPC) Period
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Baseline, Week 24
Query!
Secondary outcome [11]
0
0
Number of Participants with Abnormal ECG parameters
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Up to End of Study (Week 144)
Query!
Eligibility
Key inclusion criteria
* Adults of = 18 years of age at the time of signing the informed consent.
* Diagnosis of Myasthenia Gravis with generalized muscle weakness, meeting clinical criteria for Myasthenia Gravis Foundation of America Class II to IVa classification.
* In participants positive for Acetylcholine receptor antibody (anti-AChR) or muscle-specific kinase antibody(anti-MuSK)
* In participants that are autoantibody seronegative i.e. not positive for anti-AChR and anti-MuSK antibodies and participants who are positive for anti-low-density lipoprotein receptor-related protein 4 antibodies (anti-LRP4)
* Has a Screening and Baseline MG-ADL score more than or equal to (>=) 6 with >= 50 percentage (%) of the total score due to non-ocular symptoms. Screening and Baseline MG-ADL scores must be stable. The difference between the Screening and Baseline scores should not be more than 2 and there should be no reported MG exacerbation during the Screening period
* If treated with oral corticosteroids: should be on a stable daily dose for at least 3 months prior to and during screening. In such case, the daily dose of oral steroids should not exceed 20 milligrams(mg)/day for prednisone/ prednisolone, 16 mg/day for methylprednisolone, 3 mg/day for dexamethasone, or 80 mg for hydrocortisone or equivalent doses for other corticosteroids.
* If treated with acetylcholinesterase inhibitor should be on a stable daily dose (pyridostigmine dose = 480 mg/day or neostigmine = 300 mg/day) for at least 3 months prior to and during screening
* Have a body weight >= 40 kilograms
* Other protocol defined inclusion criteria could apply
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
No
Query!
Key exclusion criteria
* Immunologic disorder other than MG or any other condition requiring chronic oral, intravenous, intramuscular, or intraarticular corticosteroid therapy. Well-controlled thyroid disease, as per the Treating Investigator or the participants regular treating physician recorded in the source documents, is not exclusionary
* Molecularly characterized or suspected congenital myasthenic syndrome, Lambert-Eaton myasthenic syndrome, inherited myopathy, muscular dystrophy, acquired myopathy or any other neurologic or systematic disease that mimics MG muscular weakness
* Active, clinically significant viral, bacterial, or fungal infection, including brain MRI or chest X-ray findings consistent with signs of infection such as PML or TB, or any major episode of infection requiring hospitalization or treatment with parenteral anti-infectives within 8 weeks prior or during Screening, or completion of oral anti-infectives within 8 weeks prior or during Screening. Vaginal candidiasis, onychomycosis, and genital or oral herpes simplex virus considered by the Investigator to be sufficiently controlled would not be exclusionary
* Has a history of or current diagnosis of active tuberculosis (TB) or is currently undergoing treatment for latent TB infection or has an untreated latent TB infection as determined by documented results within 3 months of the Screening Visit of a positive TB skin test .
* Active malignancy, or history of cancer or signs of malignancy in any Screening assessment
* Treatment with nonsteroidal immunosuppressants, used in gMG, such as azathioprine, mycophenolate mofetil, methotrexate, cyclosporine, cyclophosphamide, tacrolimus within 4 weeks prior to randomization
* Treatment with FcRn or complement inhibitors (such as eculizumab, rozanolixizumab efgartigimod, ravulizumab, zilucoplan or nipocalimab) within 8 weeks prior to randomization
* History of thymectomy within 6 months prior to Screening.
* History of generalized seizures (except for history of febrile seizures during the participant's childhood).
* Negative or indeterminate for Varicella Zoster Virus antibodies at screening
* History of myasthenic crisis in the last 12 months prior to and during screening
* History of recurrent infections (that is 3 or more infections per year documented in available source data) within the last 2 years
* Discontinuation of treatment with any non-steroidal immunosuppressants used in gMG, such as azathioprine, mycophenolate mofetil, methotrexate, cyclosporine, cyclophosphamide, tacrolimus within the last 6 months prior to Screening
* If treated with non-steroidal immunosuppressants for gMG, the dose at Screening higher than 50 mg/day for azathioprine, 500 mg/day for mycophenolate mofetil, 1 mg/day for tacrolimus, 50 mg/day for cyclosporine, 25 mg/day for cyclophosphamide, or 7.5 mg/week for methotrexate
* Participation in clinical study of any investigational drug within 6 months, or 5 half-lives of the investigational drug used in the previous clinical study prior to randomization, whichever is longer. However, participants with any prior exposure to cladribine may not enter the study regardless of timing of exposure
* Other protocol defined exclusion criteria could apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
25/06/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
12/11/2030
Query!
Actual
Query!
Sample size
Target
264
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Brain and Mind Research Institute - Camperdown
Query!
Recruitment hospital [2]
0
0
Sunshine Coast University Hospital - Birtinya
Query!
Recruitment hospital [3]
0
0
Princess Alexandra Hospital - PARENT - South Brisbane
Query!
Recruitment hospital [4]
0
0
John Hunter Hospital - PARENT - City of Burnside
Query!
Recruitment hospital [5]
0
0
Box Hill Hospital - PARENT - Box Hill
Query!
Recruitment hospital [6]
0
0
Gold Coast University Hospital - PARENT - Southport
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
4575 - Birtinya
Query!
Recruitment postcode(s) [3]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [4]
0
0
SA 5072 - City of Burnside
Query!
Recruitment postcode(s) [5]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [6]
0
0
- Southport
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
District of Columbia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kansas
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
North Carolina
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Ohio
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
South Carolina
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Tennessee
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Texas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Vermont
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Virginia
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Wisconsin
Query!
Country [15]
0
0
Argentina
Query!
State/province [15]
0
0
Ciudad Autonoma Buenos Aires
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Córdoba
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Rosario
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
San Juan
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
San Miguel de Tucumán
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Leuven
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Liège
Query!
Country [22]
0
0
Bulgaria
Query!
State/province [22]
0
0
Montana
Query!
Country [23]
0
0
Bulgaria
Query!
State/province [23]
0
0
Pleven
Query!
Country [24]
0
0
Bulgaria
Query!
State/province [24]
0
0
Plovdiv
Query!
Country [25]
0
0
Bulgaria
Query!
State/province [25]
0
0
Sofia
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
British Columbia
Query!
Country [27]
0
0
China
Query!
State/province [27]
0
0
Anhui
Query!
Country [28]
0
0
China
Query!
State/province [28]
0
0
Beijing Municipality
Query!
Country [29]
0
0
China
Query!
State/province [29]
0
0
Guangdong
Query!
Country [30]
0
0
China
Query!
State/province [30]
0
0
Guizhou
Query!
Country [31]
0
0
China
Query!
State/province [31]
0
0
Hebei
Query!
Country [32]
0
0
China
Query!
State/province [32]
0
0
Henan
Query!
Country [33]
0
0
China
Query!
State/province [33]
0
0
Hu'nan
Query!
Country [34]
0
0
China
Query!
State/province [34]
0
0
Hubei
Query!
Country [35]
0
0
China
Query!
State/province [35]
0
0
Jilin
Query!
Country [36]
0
0
China
Query!
State/province [36]
0
0
Liaoning
Query!
Country [37]
0
0
China
Query!
State/province [37]
0
0
Shanghai Municipality
Query!
Country [38]
0
0
China
Query!
State/province [38]
0
0
Shanxi
Query!
Country [39]
0
0
China
Query!
State/province [39]
0
0
Sichuan
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Alpes Maritimes
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Bas Rhin
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Isere
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Paris
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Puy De Dome
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Rhone
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Val De Marne
Query!
Country [47]
0
0
Georgia
Query!
State/province [47]
0
0
Tbilisi
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Baden-Wurttemberg
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Lower Saxony
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
North Rhine-Westphalia
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Saxony
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Schleswig-Holstein
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Berlin
Query!
Country [54]
0
0
Greece
Query!
State/province [54]
0
0
Larissa
Query!
Country [55]
0
0
Greece
Query!
State/province [55]
0
0
Pátrai
Query!
Country [56]
0
0
Greece
Query!
State/province [56]
0
0
Thessaloniki
Query!
Country [57]
0
0
Hungary
Query!
State/province [57]
0
0
Szeged
Query!
Country [58]
0
0
India
Query!
State/province [58]
0
0
Andhra Pradesh
Query!
Country [59]
0
0
India
Query!
State/province [59]
0
0
Karnataka
Query!
Country [60]
0
0
India
Query!
State/province [60]
0
0
Maharashtra
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Bergamo
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Bologna
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Genova
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Milan
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Pavia
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Rome
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Treviso
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Chiba
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Fukuoka
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Fukushima
Query!
Country [71]
0
0
Japan
Query!
State/province [71]
0
0
Hokkaido
Query!
Country [72]
0
0
Japan
Query!
State/province [72]
0
0
Iwate
Query!
Country [73]
0
0
Japan
Query!
State/province [73]
0
0
Kagawa-ken
Query!
Country [74]
0
0
Japan
Query!
State/province [74]
0
0
Nagasaki
Query!
Country [75]
0
0
Japan
Query!
State/province [75]
0
0
Saitama
Query!
Country [76]
0
0
Japan
Query!
State/province [76]
0
0
Tokyo-To
Query!
Country [77]
0
0
Japan
Query!
State/province [77]
0
0
Suita-shi
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Gdansk
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Krakow
Query!
Country [80]
0
0
Poland
Query!
State/province [80]
0
0
Warsaw
Query!
Country [81]
0
0
Poland
Query!
State/province [81]
0
0
Zabrze
Query!
Country [82]
0
0
Romania
Query!
State/province [82]
0
0
Bucharest
Query!
Country [83]
0
0
Romania
Query!
State/province [83]
0
0
Constan?a
Query!
Country [84]
0
0
Romania
Query!
State/province [84]
0
0
Târgu Mures
Query!
Country [85]
0
0
Serbia
Query!
State/province [85]
0
0
Belgrade
Query!
Country [86]
0
0
Serbia
Query!
State/province [86]
0
0
Kragujevac
Query!
Country [87]
0
0
Serbia
Query!
State/province [87]
0
0
Niš
Query!
Country [88]
0
0
Serbia
Query!
State/province [88]
0
0
Novi Sad
Query!
Country [89]
0
0
South Korea
Query!
State/province [89]
0
0
Daegu
Query!
Country [90]
0
0
South Korea
Query!
State/province [90]
0
0
Gwangju
Query!
Country [91]
0
0
South Korea
Query!
State/province [91]
0
0
Seoul
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Barcelona
Query!
Country [93]
0
0
Spain
Query!
State/province [93]
0
0
Córdoba
Query!
Country [94]
0
0
Spain
Query!
State/province [94]
0
0
Principality of Asturias
Query!
Country [95]
0
0
Spain
Query!
State/province [95]
0
0
Valencia
Query!
Country [96]
0
0
Sweden
Query!
State/province [96]
0
0
Göteborg
Query!
Country [97]
0
0
Sweden
Query!
State/province [97]
0
0
Karlstad
Query!
Country [98]
0
0
Sweden
Query!
State/province [98]
0
0
Stockholm
Query!
Country [99]
0
0
Switzerland
Query!
State/province [99]
0
0
Bern
Query!
Country [100]
0
0
Taiwan
Query!
State/province [100]
0
0
Kaohsiung City
Query!
Country [101]
0
0
Taiwan
Query!
State/province [101]
0
0
Taichung
Query!
Country [102]
0
0
Taiwan
Query!
State/province [102]
0
0
Taipei
Query!
Country [103]
0
0
Turkey (Türkiye)
Query!
State/province [103]
0
0
Ankara
Query!
Country [104]
0
0
Turkey (Türkiye)
Query!
State/province [104]
0
0
Atakum/SAMSUN
Query!
Country [105]
0
0
Turkey (Türkiye)
Query!
State/province [105]
0
0
Istanbul
Query!
Country [106]
0
0
Turkey (Türkiye)
Query!
State/province [106]
0
0
Izmir
Query!
Country [107]
0
0
Turkey (Türkiye)
Query!
State/province [107]
0
0
Kocaeli
Query!
Country [108]
0
0
Turkey (Türkiye)
Query!
State/province [108]
0
0
Mersin
Query!
Country [109]
0
0
Turkey (Türkiye)
Query!
State/province [109]
0
0
Trabzon
Query!
Country [110]
0
0
United Kingdom
Query!
State/province [110]
0
0
Greater London
Query!
Country [111]
0
0
United Kingdom
Query!
State/province [111]
0
0
Nottinghamshire
Query!
Country [112]
0
0
United Kingdom
Query!
State/province [112]
0
0
South Yorkshire
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Query!
Address
Query!
Country
Query!
Secondary sponsor
Nil
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
EMD Serono Research & Development Institute, Inc.
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this clinical study is to determine the efficacy and safety of a new oral cladribine formulation in participants with Generalized Myasthenia Gravis (gMG) in comparison to placebo. It will also investigate the sustained efficacy, the need for retreatment, and the long-term safety of oral cladribine in gMG. An additional component is included to characterize the Pharmacokinetics (PK) of the new cladribine formulation in gMG participants. This study is divided into 3 periods: the double-blind placebo control (DBPC) pivotal period, and 2 extensions, the blinded extension (BE) and the retreatment (RT) period. Furthermore, in trial interviews will be conducted as a sub-study to MyClad with a sub-set of participants to gain an in depth understanding of the participant cladribine treatment and study experience.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06463587
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Responsible
Query!
Address
0
0
EMD Serono Research & Development Institute, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
US Medical Information
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
888-275-7376
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
IPD supporting publicly available results will be evaluated for sharing.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR), Analytic code
Query!
When will data be available (start and end dates)?
IPD from completed trials will be publicly available within 6 months after all of the following events:
* Approval of a product/new indication by major authorities (FDA, EMA, PMDA if requested) with no pending submissions
* Public results via primary manuscript or trial registry disclosure
* Legal authority to share data
* Privacy protections are in place
If approval is not sought or development is globally discontinued, data will be publicly available within 18 months after global trial completion. Further information on how to request data can be found on our website bit.ly/IPD21
Query!
Available to whom?
Qualified researchers may propose access to IPD from sponsored trials via https://vivli.org/members/ourmembers/.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://vivli.org/
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06463587
Download to PDF